N-of-One Selected by Spectrum Health to Provide Clinical Interpretation for 50-Gene Hot-Spot Solid Tumor Panel

  • Posted by Emily Haynes
  • On August 18, 2015
  • 0 Comments
– Spectrum Health Cancer Center adopts N-of-One interpretation – LEXINGTON, Mass., August 18, 2015 – N-of-One, Inc., the leader in clinical interpretation for precision medicine in oncology, today announced that it has signed an agreement with Spectrum Health to provide clinical interpretation for all cases sequenced on Spectrum Health’s 50-gene hot-spot solid tumor panel. Spectrum […]
Read More

GenomiCare Partners with N-of-One to Provide High-quality Clinical Interpretation for Comprehensive Next-generation Sequencing Tests in China

  • Posted by Emily Haynes
  • On August 5, 2015
  • 0 Comments
N-of-One to deliver internationally-leading clinical interpretation for GenomiCare’s comprehensive full-exome oncology gene panels LEXINGTON, Mass. & SHANGHAI–(BUSINESS WIRE)–N-of-One, Inc., the global leader in clinical interpretation for precision medicine in oncology, and GenomiCare Biotechnology, a fast-growing precision medicine services company headquartered in Shanghai, China, today announced a signed agreement for N-of-One to provide clinical interpretation for […]
Read More

Novogene Collaborates with Top-tier Clinical Interpretation Company N-of-One in China for Genomic Analysis to Optimize Cancer Patients’ Individualized Therapy

  • Posted by Emily Haynes
  • On August 4, 2015
  • 0 Comments
August 4, 2015 – Novogene Bioinformatics Technology Co.Ltd and N-of-One, Inc., the leading provider of clinical interpretation for precision medicine in oncology, announced a new partnership today. With this new partnership, N-of-One will provide clinical interpretation for Novogene’s comprehensive oncology panel – NovoPM™. This is the first time in China that the Novogene Medical Business […]
Read More
BACK TO
TOP
LEARN
MORE